Trial Profile
A Long-Term Safety Extension Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Ferric citrate (Primary)
- Indications Hyperphosphataemia
- Focus Therapeutic Use
- Sponsors Keryx Biopharmaceuticals
- 06 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Nov 2013 New trial record
- 07 Nov 2013 Results published in the Media Release.